Corvus Pharmaceuticals, Inc. — Net Income by Fiscal Year
12 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/29be85d8-77ca-4e9a-9ec9-55ed9d980902/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-15.3M | 2025-01-01 – 2025-12-31 | evidence 0001104659-26-048595 |
| FY 2024 | $-62.3M | 2024-01-01 – 2024-12-31 | evidence 0001104659-26-048595 |
| FY 2023 | $-27.0M | 2023-01-01 – 2023-12-31 | evidence 0001104659-26-048595 |
| FY 2022 | $-41.3M | 2022-01-01 – 2022-12-31 | evidence 0001558370-23-004792 |
| FY 2021 | $-43.2M | 2021-01-01 – 2021-12-31 | evidence 0001558370-22-003281 |
| FY 2020 | $-6.0M | 2020-01-01 – 2020-12-31 | evidence 0001558370-21-003462 |
| FY 2019 | $-46.7M | 2019-01-01 – 2019-12-31 | evidence 0001558370-20-002232 |
| FY 2018 | $-46.9M | 2018-01-01 – 2018-12-31 | evidence 0001558370-19-001660 |
| FY 2017 | $-55.7M | 2017-01-01 – 2017-12-31 | evidence 0001047469-18-001209 |
| FY 2016 | $-36.4M | 2016-01-01 – 2016-12-31 | evidence 0001047469-17-001459 |
| FY 2015 | $-31.3M | 2015-01-01 – 2015-12-31 | evidence 0001047469-17-001459 |
| FY 2014 | $-161.0k | 2014-01-27 – 2014-12-31 | evidence 0001047469-17-001459 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).